DCM
OBIO icon

DAFNA Capital Management’s Orchestra BioMed OBIO Stock Holding History

DAFNA Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$539K Hold
126,841
– – 0.12% 76
2025
Q4 		$526K Sell
126,841
-236,795
-65% -$955K 0.12% 69
2025
Q3 		$902K Buy
+363,636
New +$1M 0.22% 59

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DAFNA Capital Management's OBIO Position: Q1 2026 in Review

DAFNA Capital Management held its Orchestra BioMed (OBIO) position steady in Q1 2026 at 126,841 shares worth $539K. The position accounts for 0.12% of the portfolio, ranked #76.

DAFNA Capital Management first reported a position in OBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $902K in Q3 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • DAFNA Capital Management held 126,841 shares of Orchestra BioMed worth $539K as of Q1 2026.
  • DAFNA Capital Management left its Orchestra BioMed share count unchanged in Q1 2026.
  • Orchestra BioMed made up 0.12% of DAFNA Capital Management's portfolio in Q1 2026, its #76 holding.
  • DAFNA Capital Management first reported a position in Orchestra BioMed in Q3 2025 and has held it in 3 quarters since.
  • DAFNA Capital Management's Orchestra BioMed position peaked at $902K in Q3 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.